SS-31: Risks & Legal Status
Important safety information, risks, and regulatory status
Important Safety Warnings
- Regulatory Uncertainty After Complete Response Letter: The FDA issued a Complete Response Letter in response to the NDA submission for Barth syndrome, indicating that the submitted data were insufficient for approval. The regulatory path forward remains uncertain, and additional clinical data or analyses may be required, potentially delaying patient access for years.
Mitigation: Monitor regulatory developments from Larimar Therapeutics; the program remains active with ongoing development activities
📌TL;DR
- •4 risk categories identified
- •1 high-severity risks
- •Legal status varies by country (2 countries listed)
Risk Assessment
The pivotal TAZPOWER trial in Barth syndrome did not meet its primary endpoint with conventional statistical significance, and the EMBRACE STEMI trial also failed its primary CK-MB endpoint. While secondary endpoints and trends were supportive, the absence of definitive primary endpoint success introduces uncertainty about clinical efficacy.
Mitigation: Interpret clinical data in context of ultra-rare disease trial limitations; consider the totality of evidence including secondary endpoints, open-label extension data, and mechanistic rationale
The FDA issued a Complete Response Letter in response to the NDA submission for Barth syndrome, indicating that the submitted data were insufficient for approval. The regulatory path forward remains uncertain, and additional clinical data or analyses may be required, potentially delaying patient access for years.
Mitigation: Monitor regulatory developments from Larimar Therapeutics; the program remains active with ongoing development activities
While open-label extension studies have provided safety data over months to years of treatment in a small number of Barth syndrome patients, the long-term consequences of sustained cardiolipin stabilization and modified cytochrome c function over decades are unknown. Theoretical concerns about chronic suppression of mitochondria-mediated apoptotic pathways have not been addressed.
Mitigation: Continued monitoring through extension studies; any future approval would likely include post-marketing surveillance requirements
SS-31 is not commercially available and can only be accessed through clinical trial participation or compassionate use programs. If approved, orphan drug pricing for an ultra-rare disease indication could result in very high treatment costs. The transition from Stealth BioTherapeutics to Larimar Therapeutics has introduced additional uncertainty about access timelines.
Mitigation: Clinical trial enrollment may provide access for eligible patients; orphan drug programs may offer assistance if approved
⚠️Important Warnings
- •SS-31 (elamipretide) is an investigational compound that has not been approved by any regulatory agency for any indication. All clinical use occurs within the context of approved research protocols.
- •The FDA Complete Response Letter for the Barth syndrome NDA indicates that the regulatory agency determined the submitted evidence was insufficient to establish efficacy. This does not preclude future approval but reflects uncertainty about the clinical evidence.
- •Patients with Barth syndrome or other conditions should not discontinue existing treatments in favor of an investigational therapy without consultation with their treating physician.
- •Research-grade SS-31 obtained outside of clinical trial settings lacks the quality controls, purity verification, and sterility assurance of clinical-grade material. Use of such material carries additional risks.
- •The transition of the elamipretide development program from Stealth BioTherapeutics to Larimar Therapeutics may affect the timeline and strategy for regulatory submissions and clinical trial availability.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Prescription | Investigational drug not yet approved by FDA; accessible only through clinical trials or expanded access programs. Received Orphan Drug Designation and Fast Track Designation for Barth syndrome. NDA submitted but received Complete Response Letter. |
| European Union | Prescription | Has received Orphan Drug Designation from the European Medicines Agency for Barth syndrome. Not approved for marketing in any EU member state. Clinical trials have been conducted in European sites. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 30+ community reports
View community protocolsCritical Safety Information#
SS-31 (elamipretide/Bendavia/MTP-131) is an investigational drug that has not been approved by the United States Food and Drug Administration, the European Medicines Agency, or any other regulatory authority for any therapeutic indication. The information in this article reflects the current state of clinical development as of the last update date and should not be construed as an endorsement of SS-31 for any clinical use outside of approved research protocols.
Regulatory Risk Assessment#
FDA Complete Response Letter#
The most significant regulatory event in the SS-31 development program was the FDA's issuance of a Complete Response Letter (CRL) in response to the New Drug Application submitted by Stealth BioTherapeutics for elamipretide in Barth syndrome. A Complete Response Letter indicates that the FDA has completed its review and has determined that the application cannot be approved in its present form. The CRL for elamipretide requested additional data to support the efficacy claim.
The CRL reflects a broader challenge in ultra-rare disease drug development: the inherent tension between the statistical requirements of conventional efficacy demonstration and the practical limitations imposed by very small patient populations. The TAZPOWER trial enrolled 12 patients, which, while representing a meaningful proportion of the known Barth syndrome population, provides limited statistical power. The FDA's response suggests that the totality of evidence, including the primary endpoint trends, secondary endpoint results, and open-label extension data, did not meet the regulatory threshold for approval.
Orphan Drug and Fast Track Designations#
Elamipretide retains Orphan Drug Designation and Fast Track Designation from the FDA for the treatment of Barth syndrome. Orphan Drug Designation provides certain development incentives including tax credits, reduced regulatory fees, and seven years of market exclusivity upon approval. Fast Track Designation enables more frequent communication with the FDA and potential eligibility for expedited review. These designations remain in effect despite the CRL and reflect ongoing FDA recognition of the unmet medical need in Barth syndrome.
European Orphan Drug Designation#
The European Medicines Agency (EMA) has also granted Orphan Drug Designation for elamipretide in Barth syndrome. This designation provides similar development incentives in the European regulatory context, including protocol assistance and market exclusivity. No Marketing Authorization Application has been submitted to the EMA.
Clinical Evidence Risks#
Mixed Primary Endpoint Results#
A central risk of the SS-31 evidence base is that neither the TAZPOWER trial (Barth syndrome) nor the EMBRACE STEMI trial met their primary endpoints. While both trials showed positive trends and supportive secondary endpoints, the failure to meet pre-specified primary endpoints is a significant limitation in conventional evidence-based medicine and regulatory assessment.
In the TAZPOWER trial, the primary endpoint was the change in six-minute walk test distance. The trial showed trends toward improvement and statistically significant results on the five-times sit-to-stand secondary endpoint, but the primary analysis did not reach the threshold for statistical significance. The small sample size (n=12) means that the trial was likely underpowered to detect a moderate treatment effect.
In the EMBRACE trial, the primary endpoint of CK-MB area under the curve was not reduced by elamipretide treatment relative to placebo. Cardiac MRI secondary endpoints showed trends toward reduced infarct size, but these were not definitive.
Disease-Specific Applicability#
SS-31's clinical evidence is concentrated in Barth syndrome and heart failure. The applicability of these findings to other conditions characterized by mitochondrial dysfunction (such as primary mitochondrial myopathies with diverse genetic etiologies, age-related mitochondrial decline, or neurodegenerative diseases) has not been established. The Phase 2 PMM trial provided early-stage data in a heterogeneous mitochondrial disease population, but the 5-day treatment duration and small sample size were insufficient to draw conclusions about efficacy.
Long-Term Safety Considerations#
Sustained Cardiolipin Modulation#
SS-31 modifies the interaction between cardiolipin and mitochondrial proteins, including cytochrome c. The peroxidase activity of the cardiolipin-cytochrome c complex is a trigger for mitochondria-mediated apoptosis. Chronic suppression of this pathway through sustained SS-31 administration raises theoretical questions about the long-term consequences for cellular quality control and the elimination of damaged or dysfunctional cells.
While open-label extension studies in Barth syndrome have provided safety data over periods extending to years without evidence of adverse effects from this mechanism, the number of patients monitored and the duration of follow-up are insufficient to rule out late-onset consequences that might emerge with decades of treatment.
Immunogenicity#
As a synthetic peptide administered by subcutaneous injection, SS-31 has the potential to elicit immune responses including the development of anti-drug antibodies. Clinical trial data on immunogenicity have not been comprehensively reported in the public domain. While the small size of the tetrapeptide (639.8 Da) makes strong immunogenicity unlikely compared to larger biologic molecules, this risk cannot be fully excluded without long-term data.
Access and Cost Risks#
Current Access Limitations#
SS-31 is not commercially available anywhere in the world. Access is currently limited to participation in clinical trials or, potentially, compassionate use or expanded access programs at the discretion of the sponsor (Larimar Therapeutics) and subject to regulatory authority approval. Patients seeking access to elamipretide must meet eligibility criteria for available clinical programs.
Projected Cost Considerations#
If elamipretide receives regulatory approval for Barth syndrome, it would likely be priced in accordance with orphan drug economics, potentially resulting in very high annual treatment costs. Orphan drugs for ultra-rare diseases are typically priced at tens of thousands to hundreds of thousands of dollars per year, reflecting the small patient population, high development costs, and limited market. Access through insurance or government health programs would depend on coverage decisions that cannot be predicted prior to approval.
Program Transition Risks#
The transition of the elamipretide development program from Stealth BioTherapeutics to Larimar Therapeutics introduced commercial and strategic uncertainties. Program transitions can result in changes to development timelines, trial priorities, and regulatory strategies. Larimar Therapeutics has indicated continued commitment to the elamipretide program, but the pace of development and the resources allocated to the program under new ownership remain to be fully demonstrated.
Risk Summary Table#
| Risk Category | Severity | Key Concern | Current Status |
|---|---|---|---|
| Primary endpoint failures | Medium | Neither TAZPOWER nor EMBRACE met primary endpoints | Open-label extension data provide supporting evidence |
| FDA Complete Response Letter | High | NDA not approved; additional data required | Development continues under Larimar Therapeutics |
| Long-term safety unknowns | Medium | Chronic cardiolipin modulation effects over decades | Extension studies ongoing; no new safety signals to date |
| Access and cost | Medium | Not commercially available; orphan pricing expected | Clinical trial access only; no approved indication |
| Program transition | Medium | Change from Stealth to Larimar Therapeutics | Larimar has stated continued commitment |
Legal Status Summary#
SS-31 (elamipretide) is classified as an investigational drug in all jurisdictions. It is not approved for commercial sale or prescription use in any country. In the United States, it has received Orphan Drug Designation and Fast Track Designation from the FDA, indicating regulatory recognition of its potential but not authorization for marketing. In the European Union, it has received Orphan Drug Designation from the EMA.
Because elamipretide is an investigational new drug rather than an approved pharmaceutical or a dietary supplement, its legal status differs from both approved drugs and unregulated research chemicals. Possession and use outside of authorized research protocols may have regulatory implications depending on jurisdiction. Researchers and clinicians should ensure compliance with applicable regulations governing investigational drugs in their respective countries.
Warnings#
Patients, caregivers, and researchers should be aware that SS-31 remains an investigational compound without proven efficacy by regulatory standards. The FDA Complete Response Letter explicitly indicates that the regulatory agency found the submitted evidence insufficient to support approval. While this does not mean the drug is ineffective, it reflects genuine uncertainty about the clinical benefit that has not been resolved by available data.
Individuals with Barth syndrome or other mitochondrial disorders should not delay or discontinue established treatments based on the investigational status of elamipretide. Clinical decisions regarding access to investigational therapies should be made in consultation with physicians experienced in the relevant disease area and in accordance with applicable regulatory requirements for clinical trial participation or compassionate use.
Related Reading#
Frequently Asked Questions About SS-31
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.